Extremely early stage osteonecrosis of the femoral head in a patient with hip pain secondary systemic steroid pulse therapy for Vogt-Koyanagi-Harada syndrome: A case report  by Kuroda, Yutaka et al.
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INTRODUCTION:  Osteonecrosis  of  the  femoral  head  (ONFH)  is  a corticosteroid-associated  disease  that
mostly cause  femoral  head  collapse  and  gait  disturbance.  At the  ﬁnal  stage  of  ONFH,  the  most  reliable
treatment  is total  hip  arthroplasty  even  in young  patients.  Although  magnetic  resonance  imaging  (MRI)
is  useful  for  early  diagnosis,  initial  stages  are  asymptomatic,  with  pain  intensifying  after  femoral  head
collapse.
PRESENTATION  OF  CASE:  A  34-year-old  female  patient  with  rapid  bilateral  loss  of  vision  was  diagnosed
Vogt-Koyanagi-Harada  syndrome.  She  immediately  received  corticosteroid  pulse  therapy.  While  under-
going therapy,  she  complained  of groin  pain.  The initial  MRI  of the  hip  did not show  abnormal  ﬁndings.
As  the right  proximal  thigh  pain  progressed,  an  MRI of  the  lumbar  spine  was  performed.  No  compression
of  the spinal  cord  was  observed,  and  right  ONFH  was  suspected  on the  basis  of  a  characteristic  band
image.  The  patient  was  diagnosed  with  Stage  1  ONFH  7 weeks  after  the  initial  symptoms.  She  was suc-
cessfully  treated  by  joint-preserving  regenerative  therapy  using  growth  factor.  After  surgery,  the  patient
completely  recovered  from  pain.
DISCUSSION:  The  occurrence  of  hip  pain  while  receiving  corticosteroid  therapy  was very  rare.  The  present
case  was  considered  a  result  of reduction  of the  blood  supply  to the  femoral  head  induced  by hip  pain
that  progressed  to ONFH  for unknown  reasons.
CONCLUSION:  It  is difﬁcult  to identify  cases  of  corticosteroid-associated  ONFH  even  in patients  with
potential  risk.  In this  case,  we  could  identify  the  patient  extremely  early  based  on the  ONFH  image  and
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. Introduction
Osteonecrosis of the femoral head (ONFH) is an intractable dis-
ase that causes progressive femoral head collapse, severe pain,
nd gait disturbance [1,2]. Although the etiology of ONFH has yet
o be fully elucidated, background factors, such as corticosteroid
se and alcohol abuse, have been indicated. The 30 s and 40 s are
usceptible ages for disease onset. The most important factor affect-
ng the fate of ONFH patients is the presence or absence of femoral
ead collapse. The ﬁnal stage of ONFH comprises severe secondary
steoarthritis of the hip joint, and the optimal treatment is total hip
rthroplasty (THA), even in young patients. In daily clinical prac-
ice, even if the diagnosis is established, 80% of untreated patients
xperience femoral head collapse and have to undergo THA [3].
ecause the collapse rate of ONFH is high [4], a recent strategy of
Abbreviations: ONFH, osteonecrosis of the femoral head; MRI, magnetic reso-
ance imaging; THA, total hip arthroplasty; VKH, Vogt-Koyanagi-Harad.
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shed  by  Elsevier  Ltd  on behalf  of IJS  Publishing  Group  Ltd.  This  is  an  open
 BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ONFH treatment has shifted the approach to early diagnosis and
early intervention [1,5]. Many joint-preserving therapies are being
studied for the purpose of preventing femoral head collapse [6–13].
Magnetic resonance imaging (MRI) can be useful for early diagno-
sis, but the symptoms corresponding to the initial stage are usually
absent or present as slight pain, that intensiﬁes after the femoral
head collapses. Several months to several years can elapse from the
occurrence of asymptomatic ONFH and the onset of symptomatic
ONFH [4]. A limitation of this study is that it may  only determine
the reason for the difference in the occurrence and the onset of
ONFH. Here we  describe a rare ONFH case associated with groin
pain during intravenous corticosteroid pulse therapy, which was
diagnosed at an extremely early stage of ONFH, and could be treated
with joint-preserving regenerative therapy.
2. Presentation of caseA 34-year-old woman  was  hospitalized in the emergency
department with rapid bilateral loss of vision, at the end of 2012.
At the prodromal stage, 10 days earlier, she presented with unex-
plained bilateral visual symptoms, headache, and deafness. On
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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F Harada (VKH) syndrome, the patient received 3 courses of systemic steroid pulse therapy
i ging.
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iig. 1. Progress information of the patient. Because of recurrence of Vogt-Koyanagi-
n  1 month. ONFH, osteonecrosis of the femoral head; MRI, magnetic resonance ima
undus observation, both bilateral uveitis and a sunset fundus were
onﬁrmed. After evaluating these clinical ﬁndings and symptoms,
he was diagnosed with Vogt-Koyanagi-Harada (VKH) syndrome.
he immediately received systemic steroid pulse therapy. The
rst course comprised 200 mg,  150 mg,  and 100 mg  of methyl-
rednisolone administered intravenously for 3 days each, followed
y a dose of 50 mg for 2 days. However, her symptoms did not
mprove. Thus, a second course of 1000 mg  corticosteroid therapy
as administered for 3 days starting on day 12 after initial diag-
osis. Weak eyesight improved; administration of corticosteroid
as gradually tapered to 30 mg/day. However, at 1 month after
nitial diagnosis, she developed panuveitis, alopecia, and extensive
epigmentation of body hair. Clinical recurrence of VKH syndrome
as observed. Next, she received third corticosteroid pulse therapy.
fter three courses of steroid pulse therapy, vision loss improved.
dministration of corticosteroid was gradually tapered to 5 mg/day
nd switched to low-dose oral drugs (Fig. 1).
On the third day of the second course of systemic steroid
ulse therapy, 2 h after receiving 1000 mg  corticosteroids, she com-
lained of acute bilateral groin pain when walking. This noticeable
ymptom was recorded, and she could still clearly remember the
ituation. Several days had been passed without any decrease in
roin pain, and she was referred to our department. An orthope-
ic doctor suspected a case of steroid induced ONFH; however,
here were no abnormal signs in the MRI  scan of the hip joints and
hysical examination (Fig. 2). We  observed the evolution of her con-
ition and avoided the administration of analgesics. Subsequently,
ncomfortable bilateral pain around the groin and proximal thigh
ontinued for 1 month. She consulted the orthopedic department
gain. To exclude the possibility of neurological symptoms from
he lumbar spine, radiographs and MRI  of the lumbar spine was
erformed. Although, there was no compression of the spinal cord,
he scout view of T2-weighted MRI  showed a characteristic band
mage consistent with ONFH. Thus, she was diagnosed with stage 1
NFH in the right hip (Fig. 3). After unilateral ONFH diagnosis, she
omplained of continuous and severe right hip joint pain. Imme-
iately, we started a clinical trial of regenerative therapy using
rowth factor for patients with precollapse stage of ONFH. This con-
isted of the clinical application of recombinant human ﬁbroblast
rowth factor-2-impregnated gelatin hydrogel. The patient agreed
nd provided written informed consent to participate in this clin-
cal trial and was surgically treated on April 2013. Three monthsFig. 2. Magnetic resonance imaging obtained after the onset of bilateral groin pain.
There were no signiﬁcant ﬁndings.
postoperatively, the severe pain disappeared completely with full
marks in the Harris hip score. Three clinical scores improved 2 years
postoperatively (visual analog scale for pain, 0 mm;  University of
California, Los Angeles [UCLA] activity score, 7; and Harris hip score,
100.0 points) compared with those preoperatively (visual analog
scale for pain, 41.0 mm;  UCLA activity score, 4; Harris hip Score,
57.0 points) (Table 1). Two years after the surgery, radiographic
regeneration of ONFH was observed without femoral head collapse.
Radiographs, computed tomography images, and MRI  showed bone
regeneration in the area of ONFH (Fig. 4).
3. DiscussionONFH and VKH syndrome are rare and intractable diseases in
Europe. Conversely, in Asia, VKH syndrome is one of the most
common causes of panuveitis [14]. Because of the high rate of
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Fig. 3. Right osteonecrosis of the femoral head could be diagnosed by magnetic resonance imaging (MRI). Characteristic band pattern was shown (yellow arrows). The scout
view  of T2-weighted MRI  (A) and T1-weighted MRI  (B).
Table 1
Clinical outcomes.
Score (range) Preoperation 3 months postoperatively 6 months postoperatively 12 months postoperatively 24 months postoperatively
VAS (0–100) 41.0 0 0 0 0
UCLA  (1–10) 4 6 6 7 7
HHS  (0–100) 57.0 100.0 100.0 100.0 100.0
Abbreviations: VAS, visual analog scale for pain; UCLA, UCLA activity rating; HHS, Harris hip Score.
Fig. 4. A schema and radiological results of the regenerative therapy. Dashed yellow lines show the border of ONFH area. (A) A schema of the surgical procedure administering
the  rhFGF-2 gelatin hydrogel by the percutaneous technique. The actual hydrogel (small photograph). (B) A screenshot used for preoperative planning. The area of osteonecrosis
of  the femoral head (ONFH) is shown in yellow. The route of the drilling is shown by the blue screw. Pre-operative magnetic resonance imaging (MRI) (C) and 2-year
postoperative radiographs show bone formation within the ONFH area: radiograph (D), computed tomography (CT) image (E), and T1-weighted MRI  (F).
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linical recurrence in patients with VKH syndrome, early high-
ose corticosteroid therapy is essential for treatment [15]. First,
e describe a rare case of VKH syndrome associated with groin
ain and treated with systemic corticosteroid therapy, with ONFH
nset 7 weeks later. In routine clinical practice, most of the
NFH cases are usually diagnosed after the femoral head col-
apses. There are several reports indicating that uveitis patients
ith systemic disorders, who require corticosteroid therapy, have
 potential risk of developing ONFH. Peretz et al. reported that
atients with uveitis and systemic diseases, including sarcoidosis,
pondyloarthropathy, Behcet’s disease, Crohn’s disease, Cushing’s
yndrome, osteoporosis, cataracts, and ONFH, required corticos-
eroids or immunosuppressive drugs and were at risk of presenting
ide effects [16]. To the best our knowledge, this is the second
ase of ONFH following VKH syndrome. Smith et al. reported
hat 6 uveitis patients with ONFH were identiﬁed including 1
atient with VKH syndrome, comprising a prevalence of 0.25%
or VKH syndrome. They concluded that corticosteroid-associated
NFH is a rare but serious complication in uveitis; a higher level
f suspicion for ONFH may  be warranted in patients with sys-
emic corticosteroid use [17]. It is difﬁcult to predict the onset of
orticosteroid-associated ONFH, even in the patients with potential
isk. In this study, we showed that repeated clinical examina-
ions and MRI  evaluations were useful in diagnosing ONFH at an
xtremely early stage.
In this case, why the patient complained of groin pain while
eceiving corticosteroid therapy was unclear. Because ONFH is con-
idered to be caused by the critical loss of the vascular supply to
he femoral head, several causative factors may  inﬂuence its devel-
pment, including hypercoagulation, bone marrow fat embolisms,
nd elevation of intraosseous pressure in the femoral head [1,2].
ome of these complex factors may  induce groin pain immediately
fter receiving systemic corticosteroid therapy, but further study is
eeded to clarify the mechanism of pain.
The patient could be successfully treated by regenerative ther-
py using growth factor. This surgical treatment is based on
ranslational clinical research in an experimental animal study
y the authors [18]. We  reported the ﬁrst clinical application
f recombinant human ﬁbroblast growth factor-2-impregnated
elatin hydrogel for patients with precollapse stage of ONFH
ith good clinical results and safety [11]. Femoral head collapse
rogresses until severe secondary osteoarthritis develops, destroy-
ng both the femoral head and the acetabulum. End-stage ONFH
atients usually require THA which involves risk of infection, dis-
ocation, revision, and limitation of sports activities throughout the
atient’s life. Considering the age of ONFH patients and high col-
apse rate of ONFH, recent therapy for ONFH is aimed at inducing
one regeneration to prevent femoral head collapse [19]. This novel
reatment strategy has shifted the concept of early diagnosis and
ggressive intervention. In particular, to prevent femoral head col-
apse, precollapse stage of ONFH has become a research target for
arious regenerative therapies, such as cell therapy [6–8], bone
ubstitutes [9,10], and growth factors [11–13]. In any case, early
iagnosis of ONFH is crucial to allow prevention of femoral head
ollapse using recently developed therapies.
. Conclusion
We  experienced a rare ONFH case associated with groin pain
uring intravenous corticosteroid pulse therapy for VKH syndrome.
ith careful attention, the patient was diagnosed with ONFH
t an extremely early stage, which allowed the application of
oint-preserving therapy. ONFH appears to be a rare and seri-
us complication in uveitis patients; thus, physicians should pay
lose attention to the patient’s complaint for early and accurate
iagnosis.
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